On Feb. 19, 2026, the U.S. Centers for Disease Control and Prevention (CDC) reported severe outcomes from COVID-19 and respiratory syncytial virus (RSV) continue to occur, especially among young children and older adults. COVID-19 was associated with an estimated 290,000–450,000 hospitalizations and 34,000–53,000 deaths; RSV was associated with 190,000–350,000 hospitalizations and 10,000–23,000 deaths.

All sequenced circulating U.S. SARS-CoV-2 viruses remained descendants of the JN.1 variant, representing the first season without a SARS-CoV-2 strain replacement since the beginning of the COVID-19 pandemic.

The highest COVID-19–associated hospitalization rates were reported among adults aged ≥75 years (932.6 per 100,000 persons), infants aged <6 months (285.6), and adults aged 65–74 years (274.4). RSV-associated hospitalization rates were highest among infants aged <12 months (1,116.7 per 100,000; 95% CI = 1,078.4–1,157.9), children aged 12–23 months (770.6; 95% CI = 743.1–800.3), and adults aged ≥75 years (426.9; 95% CI = 366.6–510.8).

COVID-19 was associated with an estimated 290,000–450,000 hospitalizations and 34,000–53,000 deaths; RSV was associated with 190,000–350,000 hospitalizations and 10,000–23,000 deaths.

All circulating SARS-CoV-2 lineages were Omicron JN.1 descendants. Staying up to date with recommended COVID-19, RSV, and influenza vaccinations remains important to reducing the risk for severe disease caused by these viruses.